Korlyns Therapeutics Ltd 6215455 false 2023-06-01 2024-05-31 2024-05-31 The principal activity of the company is the distribution and licensing of generic pharmaceutical products and equipment. Digita Accounts Production Advanced 6.30.9574.0 true 6215455 2023-06-01 2024-05-31 6215455 2024-05-31 6215455 core:CurrentFinancialInstruments core:WithinOneYear 2024-05-31 6215455 bus:Micro-entities 2023-06-01 2024-05-31 6215455 bus:AuditExemptWithAccountantsReport 2023-06-01 2024-05-31 6215455 bus:FilletedAccounts 2023-06-01 2024-05-31 6215455 bus:SmallCompaniesRegimeForAccounts 2023-06-01 2024-05-31 6215455 bus:RegisteredOffice 2023-06-01 2024-05-31 6215455 bus:CompanySecretary1 2023-06-01 2024-05-31 6215455 bus:Director1 2023-06-01 2024-05-31 6215455 bus:PrivateLimitedCompanyLtd 2023-06-01 2024-05-31 6215455 countries:AllCountries 2023-06-01 2024-05-31 6215455 2022-06-01 2023-05-31 6215455 2023-05-31 6215455 core:CurrentFinancialInstruments core:WithinOneYear 2023-05-31 iso4217:GBP xbrli:pure

Registration number: 6215455

Korlyns Therapeutics Ltd

Unaudited Filleted Financial Statements

for the Year Ended 31 May 2024

[FRS 105 Micro Entities]
[FILLETED FOR FILING PURPOSES]

 

Korlyns Therapeutics Ltd

Contents

Company Information

1

Balance Sheet

2 to 3

Notes to the Unaudited Financial Statements

2

 

Korlyns Therapeutics Ltd

Company Information

Director

C Iriajen

Company secretary

E Iriajen

Registered office

10 Linkfield Lane
Redhill
Surrey
RH1 1JL

Accountants

Tremaines Ltd
East Wing, South Hill
Paddockhurst Road
Turners Hill
West Sussex
RH10 4SF

 

Korlyns Therapeutics Ltd

(Registration number: 6215455)
Balance Sheet as at 31 May 2024

2024
£

2023
£

Current assets

157,426

118,414

Creditors: Amounts falling due within one year

(82,986)

(50,117)

Total assets less current liabilities

74,440

68,297

Accruals and deferred income

(18,022)

(240)

 

56,418

68,057

Capital and reserves

56,418

68,057

1

General information

The company is a private company limited by share capital, incorporated in UK.

The address of its registered office is:
10 Linkfield Lane
Redhill
Surrey
RH1 1JL

These financial statements were authorised for issue by the director on 27 February 2025.

Basis of preparation

The financial statements have been prepared under the historical cost convention and in accordance with FRS 105 'The Financial Reporting Standard applicable to the Micro-entities Regime'.

2

Staff numbers

The average number of persons employed by the company (including the director) during the year, was 4 (2023 - 4).

For the financial year ending 31 May 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and

The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the micro-entity provisions of the Companies Act 2006 and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime. As permitted by section 444 (5A) of the Companies Act 2006, the director has not delivered to the registrar a copy of the Profit and Loss Account.

 

Korlyns Therapeutics Ltd

(Registration number: 6215455)
Balance Sheet as at 31 May 2024

Approved and authorised by the director on 27 February 2025
 

.........................................
C Iriajen
Director